Personalized Prediction of Neurodegenerative Outcomes

Full study title: Improving prognostic confidence in neurodegenerative diseases causing dementia using peripheral biomarkers and integrative modeling

 

What is the study about?

This study aims to improve diagnostic accuracy of neurodegenerative diseases and figuring out how they might progress. The study will do this by looking at your blood, results of cognitive questionnaires and information from a clinical checkup. It’s often hard to get the diagnosis right for diseases causing dementia, and predicting progression is difficult. It’s important to get the right diagnosis quickly so that the right treatments and supports can be offered. A lumbar puncture and skin biopsy are optional and can be used to measure proteins related to neurodegenerative diseases.

 

Eligibility – Who can participate?

Participants must:

• Have a diagnosis of mild cognitive impairment (MCI) or dementia
• Be 30 to 95 years of age
• Have a study partner who has some weekly contact with you and can answer questions regarding your memory and functioning

 

Time requirement

3 visits over 1 year. Study visits occur every 6 months and include questionnaires, blood collection, and optional procedures such as a lumbar puncture and a skin biopsy.

 

TDRA study investigators

Drs. Carmela Tartaglia, David Tang-Wai, Morris Freedman, Ekaterina Rogaeva, Dan Felsky, Sanjeev Kumar, Sandra Black, and Tarek Rajji

 

More information

Toronto Dementia Research Alliance (TDRA) Coordinated Studies List: TDRA Coordinated Studies | Dementia Research (utoronto.ca)

TDRA Site:

Baycrest,

Address: 3560 Bathurst St, North York, ON M6A 2E1

Centre for Addiction and Mental Health (CAMH),

Address: 1001 Queen St W, Toronto, ON M6J 1H4

Sunnybrook Health Sciences Centre,

Address: 2075 Bayview Ave, Toronto, ON M4N 3M5

University Health Network (UHN)-Toronto Western Hospital,

Address: 399 Bathurst Street, Toronto ON M5T 2S8

Age Group:

30 - 39, 40 - 49, 50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 80, 81 - 85, 86 - 90, 91+

Target Population:

Alzheimer’s disease, Corticobasal Syndrome (CBS), Dementia with Lewy bodies (DLB), Frontotemporal dementia (FTD), Mild cognitive impairment, Parkinson’s disease, Vascular dementia